Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 16/20 | 0.66 |
| ▸ | MTTP | P55157 | 6/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12174513 | 0.94 | NPY2R (0.58) | NPY2RMTTPCHRM1CHRM2CHRM4 | |
| SCHEMBL12174495 | 0.93 | NPY2R (0.66) | NPY2RMTTP | |
| SCHEMBL12174463 | 0.91 | NPY2R (0.54) | NPY2RMTTPNPC1RAB9AKMT2A | |
| SCHEMBL12174421 | 0.91 | NPY2R (0.75) | NPY2RMTTPKMT2A | |
| SCHEMBL12174470 | 0.91 | NPY2R (0.67) | NPY2RMTTPNPC1L3MBTL1 | |
| SCHEMBL12174537 | 0.91 | NPY2R (0.67) | NPY2RMTTP | |
| SCHEMBL12174407 | 0.90 | NPY2R (0.66) | NPY2RMTTPKMT2A | |
| SCHEMBL12174453 | 0.90 | NPY2R (0.64) | NPY2RMTTPCHRM1RAB9AKMT2A | |
| SCHEMBL12174518 | 0.88 | NPY2R (0.66) | NPY2RMTTP | |
| SCHEMBL12174471 | 0.87 | NPY2R (0.65) | NPY2RMTTPNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354402-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-15 | — | — | US | disclosed |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2011-11-03 | — | — | US | disclosed |
| EP-1317431-B1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-20 | — | — | EP | disclosed |
| US-7528154-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICAL N.V. (BE) | 2009-05-05 | — | — | US | disclosed |
| US-7528154-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICAL N.V. (BE) | 2009-05-05 | — | — | US | disclosed |
| US-20080125412-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2008-05-29 | — | — | US | disclosed |
| US-20080125412-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2008-05-29 | — | — | US | disclosed |
| US-7253157-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| US-7253157-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| EP-1806341-A2 | (+)Phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester as lipid lowering agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2007-04-12 | — | — | US | disclosed |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | MEERPOEL LIEVEN | 2007-04-12 | — | — | US | disclosed |
| US-7169796-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-30 | — | — | US | disclosed |
| US-7169796-B2 | Polyarylcarboxamides useful as lipid lowering agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125412-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | NPY2R 4187/4885MTTP 9/4885CHRM1 4850/4885 |
| US-20110269747-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | NPY2R 4187/4885MTTP 9/4885CHRM1 4850/4885 |
| US-20070082888-A1 | POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS | LIPC, PNLIP, APOB | NPY2R 4187/4885MTTP 9/4885CHRM1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.